{
    "organizations": [],
    "uuid": "5b51891a36be3539c26d9f0f8b6b556dd7c4daea",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-innate-pharma-fy-net-results-swing/brief-innate-pharma-fy-net-results-swings-to-loss-of-48-4-million-euros-idUSW8N1KI009",
    "ord_in_thread": 0,
    "title": "BRIEF-Innate Pharma FY Net Results Swings To Loss Of 48.4‍​ Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - INNATE PHARMA SA:\n* FY REVENUE AND OTHER INCOME EUR 44.0‍​ MILLION VERSUS EUR 65.7 MILLION YEAR AGO\n* FY OPERATING LOSS EUR 40.0‍​ MILLION VERSUS INCOME EUR 7.6 MILLION YEAR AGO\n* FY NET LOSS EUR 48.4‍​ MILLION VERSUS INCOME EUR 12.6 MILLION YEAR AGO\n* CASH, CASH EQUIVALENTS AND FINANCIAL ASSETS AMOUNTED TO EUR 176.6 MILLION AS OF DEC. 31\n* IPH5401 WILL ENTER FIRST CLINICAL STUDIES IN ONCOLOGY IN 2018\n* EXPECTS CLINICAL READ-OUTS FOR BOTH MONALIZUMAB AND IPH4102 PROGRAM IN 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-08T14:26:00.000+02:00",
    "crawled": "2018-03-09T14:39:09.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "innate",
        "pharma",
        "sa",
        "fy",
        "revenue",
        "income",
        "eur",
        "million",
        "versus",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "operating",
        "loss",
        "eur",
        "million",
        "versus",
        "income",
        "eur",
        "million",
        "year",
        "ago",
        "fy",
        "net",
        "loss",
        "eur",
        "million",
        "versus",
        "income",
        "eur",
        "million",
        "year",
        "ago",
        "cash",
        "cash",
        "equivalent",
        "financial",
        "asset",
        "amounted",
        "eur",
        "million",
        "iph5401",
        "enter",
        "first",
        "clinical",
        "study",
        "oncology",
        "expects",
        "clinical",
        "monalizumab",
        "iph4102",
        "program",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}